We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+9.46%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$11.9B
AUM Growth
+$1.4B
(+13%)
Cap. Flow
+$748M
Cap. Flow
% of AUM
6.3%
Top 10 Holdings %
Top 10 Hldgs %
12.11%
Holding
747
New
202
Increased
220
Reduced
153
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$134M |
| 2 |
STMicroelectronics
STM
|
+$103M |
| 3 |
Meta Platforms (Facebook)
META
|
+$89.9M |
| 4 |
MetLife
MET
|
+$71.9M |
| 5 |
Gilead Sciences
GILD
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TE Connectivity
TEL
|
+$161M |
| 2 |
Eli Lilly
LLY
|
+$153M |
| 3 |
MRSH
Marsh
MRSH
|
+$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$91.8M |
| 5 |
Electronic Arts
EA
|
+$79.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.43% |
| 2 | Technology | 17.4% |
| 3 | Industrials | 8.07% |
| 4 | Energy | 6.4% |
| 5 | Financials | 6.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Meta Platforms (Facebook)
META
$1.51T
| $242M | 2.04% |
422,215
+174,625
| +71% | +$89.9M |
|
|
2
Gilead Sciences
GILD
$161B
| $162M | 1.36% |
1,928,029
+921,537
| +92% | +$70.3M |
|
3
AbbVie
ABBV
$458B
| $160M | 1.35% |
808,736
+58,414
| +8% | +$10.9M |
|
4
Revolution Medicines
RVMD
$40.2B
| $156M | 1.31% |
3,433,713
+142,922
| +4% | +$6.22M |
|
5
Vaxcyte
PCVX
$7.89B
| $126M | 1.06% |
1,103,945
+397,042
| +56% | +$35.8M |
|
|
6
ASML
ASML
$675B
| $125M | 1.05% |
+149,876
| New | +$134M |
|
|
NUVL
7
DELISTED
Nuvalent
NUVL
| $122M | 1.03% |
1,193,679
+307,602
| +35% | +$25.5M |
|
|
PR
8
Permian Resources
PR
$17.9B
| $118M | 1% |
8,683,996
+1,714,665
| +25% | +$25.2M |
|
9
Ovintiv
OVV
$17.7B
| $114M | 0.96% |
2,984,213
-1,069,527
| -26% | -$46.2M |
|
10
Keysight
KEYS
$54.5B
| $113M | 0.95% |
712,588
+89,887
| +14% | +$12.8M |
|
11
Danaher
DHR
$135B
| $109M | 0.92% |
393,300
+144,918
| +58% | +$38.4M |
|
12
Aon
AON
$77.3B
| $107M | 0.9% |
309,754
+196,602
| +174% | +$64.3M |
|
|
13
STMicroelectronics
STM
$46B
| $105M | 0.89% |
3,542,770
+3,109,902
| +718% | +$103M |
|
|
14
Regeneron Pharmaceuticals
REGN
$68.8B
| $105M | 0.88% |
99,417
-82,480
| -45% | -$91.8M |
|
15
EQT Corp
EQT
$33.2B
| $103M | 0.87% |
2,818,470
+622,034
| +28% | +$21.2M |
|
16
L3Harris
LHX
$55.9B
| $103M | 0.87% |
432,141
+104,065
| +32% | +$24M |
|
17
Gulfport Energy Corp
GPOR
$2.83B
| $102M | 0.86% |
675,342
+264,523
| +64% | +$38.8M |
|
|
18
Eli Lilly
LLY
$1.07T
| $101M | 0.85% |
114,427
-170,162
| -60% | -$153M |
|
19
Roivant Sciences
ROIV
$25.2B
| $100M | 0.84% |
8,686,476
+685,537
| +9% | +$7.8M |
|
20
Amgen
AMGN
$203B
| $99.2M | 0.84% |
307,950
+15,817
| +5% | +$5.17M |
|
21
Zimmer Biomet
ZBH
$17.7B
| $99M | 0.83% |
916,927
-275
| -0% | -$30K |
|
22
Merck
MRK
$324B
| $96.4M | 0.81% |
848,649
+137,296
| +19% | +$16.3M |
|
23
Chord Energy
CHRD
$7.79B
| $83.8M | 0.71% |
643,518
-110,738
| -15% | -$17M |
|
24
Celldex Therapeutics
CLDX
$2.77B
| $79.6M | 0.67% |
2,341,121
+1,583,350
| +209% | +$60.3M |
|
|
25
MetLife
MET
$61B
| $79.4M | 0.67% |
+962,451
| New | +$71.9M |
|
Similar funds
KAS
PAM
TCIIS
Woodline Partners's Q3 2024 Portfolio in Review
As of Q3 2024, Woodline Partners held 747 positions worth $11.9B, up 13% from $10.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Woodline Partners deployed $748M of net new capital in Q3 2024, opening 202 new positions and adding to 220 existing holdings. Its largest new stake was ASML: 149,876 shares worth $125M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 42% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Eli Lilly, an estimated $153M trimmed.
- Woodline Partners's largest Q3 2024 buy was ASML: 149,876 shares worth $125M.
- Woodline Partners added most to STMicroelectronics in Q3 2024, an estimated $103M increase.
- Woodline Partners's biggest Q3 2024 reduction was Eli Lilly, cutting an estimated $153M.
- Woodline Partners fully exited TE Connectivity in Q3 2024, selling an estimated $161M.
- Woodline Partners's ten largest holdings make up 12% of its $11.9B portfolio in Q3 2024.
- Woodline Partners opened 202 new positions and closed 161 in Q3 2024.
- Woodline Partners's portfolio value rose 13% quarter-over-quarter to $11.9B.
Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.